This podcast, based on GEP's bulletin, Nearshoring Decision Framework for Life Sciences: What to Move, Where, and When, explains why proximity alone won't guarantee resilience, and how leaders can tell whether a nearshoring move reduces risk or just moves it somewhere else.
Flagging which APIs concentrate in a single region isn't hard. A quick spend review handles that. The harder question is whether Mexico or another alternative genuinely lowers risk once qualification timelines and new compliance costs enter the picture. Miss that step, and a well-intentioned footprint shift can end up adding exposure instead of removing it.
What makes the difference? Modeling. A risk-adjusted framework weighs total landed cost against disruption scenarios and qualification speed, catching exposure before it turns into a shortage. A straight geography swap skips that step, moving production without weighing whether the new location holds up under disruption. It just changes the address on the risk, while layering on a fresh set of regulatory and qualification requirements.
What's Inside
- A three-layer framework for risk-adjusted cost modeling
- Why qualification speed decides real-world resilience
- Which products and steps to move first, and why
Smarter nearshoring decisions start before the footprint moves.
Listen to the podcast now.
FAQs
In this context, nearshoring means moving pharmaceutical or API production closer to the point of use, often from Asia to nearer markets such as Mexico. The podcast explains that proximity alone offers no guarantee of lower risk, since new qualification, regulatory, and reliability requirements typically apply to the new location.
Qualifying a new API supplier in regulated pharma manufacturing averages 18 to 24 months, often longer for finished dosage. The podcast covers why that timeline needs to shape the nearshoring strategy from the start, since a cost-effective option that takes years to qualify offers little protection against near-term disruption.
No. The podcast explains that moving everything at once often creates new concentration in a different region instead of reducing it. It outlines how to identify which products and process steps are both most exposed to disruption and realistic to qualify quickly, so nearshoring efforts target the areas where they matter most.